Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale.
Clinical trial
ESUS
Embolic strokes of undetermined source
Functional scale
Journal
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
18
11
2021
revised:
01
01
2022
accepted:
15
01
2022
pubmed:
7
2
2022
medline:
25
3
2022
entrez:
6
2
2022
Statut:
ppublish
Résumé
Function is an important outcome after stroke; traditional assessments may not capture functional deficits important to patients. We examined the validity of the Standard Assessment of Global Everyday Activities (SAGEA), a patient-reported outcome that assesses activities important to patients and for use in international clinical trials. The NAVIGATE-ESUS trial evaluated rivaroxaban compared to aspirin in preventing recurrent stroke in 7213 participants. The Modified Rankin Scale (mRS), the National Institutes of Health Stroke Scale (NIHSS), and the SAGEA were collected at entry. Chi square tests were used to compare proportions and Spearman rank correlations were used to compare between measures. SAGEA was compared to the Modified Frailty Index (MFI) and the occurrence of infarct to examine criterion validity RESULTS: Participants were 67 years, 2/3 were male, and at baseline 30% had no disability and 58% had slight disability according to mRS scores. SAGEA was weakly correlated with the mRS (r=0.37), the NIHSS (r=0.29) and the MFI (r=0.30). Of the 2154 with an mRS score of 0, 61% reported difficulty on the SAGEA. The largest discrepancies between SAGEA and other measures were because of cognitive functional deficits detected by the SAGEA that were not identified on other assessments. A larger number of MRI identified infarcts (acute and covert) were associated with a higher SAGEA score (p=0.007). The SAGEA is a simple, globally applicable measure of cognitive and functional abilities that identifies issues that other commonly used assessments of disability and function do not capture.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Function is an important outcome after stroke; traditional assessments may not capture functional deficits important to patients. We examined the validity of the Standard Assessment of Global Everyday Activities (SAGEA), a patient-reported outcome that assesses activities important to patients and for use in international clinical trials.
METHODS
METHODS
The NAVIGATE-ESUS trial evaluated rivaroxaban compared to aspirin in preventing recurrent stroke in 7213 participants. The Modified Rankin Scale (mRS), the National Institutes of Health Stroke Scale (NIHSS), and the SAGEA were collected at entry. Chi square tests were used to compare proportions and Spearman rank correlations were used to compare between measures. SAGEA was compared to the Modified Frailty Index (MFI) and the occurrence of infarct to examine criterion validity RESULTS: Participants were 67 years, 2/3 were male, and at baseline 30% had no disability and 58% had slight disability according to mRS scores. SAGEA was weakly correlated with the mRS (r=0.37), the NIHSS (r=0.29) and the MFI (r=0.30). Of the 2154 with an mRS score of 0, 61% reported difficulty on the SAGEA. The largest discrepancies between SAGEA and other measures were because of cognitive functional deficits detected by the SAGEA that were not identified on other assessments. A larger number of MRI identified infarcts (acute and covert) were associated with a higher SAGEA score (p=0.007).
CONCLUSIONS
CONCLUSIONS
The SAGEA is a simple, globally applicable measure of cognitive and functional abilities that identifies issues that other commonly used assessments of disability and function do not capture.
Identifiants
pubmed: 35124321
pii: S1052-3057(22)00026-X
doi: 10.1016/j.jstrokecerebrovasdis.2022.106329
pii:
doi:
Substances chimiques
Rivaroxaban
9NDF7JZ4M3
Aspirin
R16CO5Y76E
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106329Subventions
Organisme : Chief Scientist Office
ID : SCAF/17/01
Pays : United Kingdom
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest J.B. received fees for an Advisory Board and as an Adjudication Committee Member from Bayer, outside the submitted work. M.S. reports personal fees from BMS and Daichii Sankyo, outside the submitted work. M.C. received a travel grant from Boehringer Ingelheim and Bayer for conference attendance. W.W. is supported by a Scottish Senior Clinical Fellowship [CSO SCAF/17/01] and received grants from the Alzheimer's Society [UK], Chief Scientist's Office, UK MRC, and the UK Stroke Association. S.Y. is supported by the Heart & Stroke Foundation/Marion W. Burke Chair in Cardiovascular Disease and has received research grants, honoraria and travel expenses for lectures from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb AstraZeneca and Sanofi, outside the submitted work. R.H. reports grants and personal fees from Bayer AG, outside the submitted work.